UPTRAVI® IV

UPTRAVI®: Available for Intravenous Use

campaign_image_7
4.5_uninterrupted_treatment--mobile.png

UPTRAVI® IV IS FOR THE TREATMENT OF PAH (WHO GROUP I) IN FC II-III PATIENTS WHO ARE TEMPORARILY UNABLE TO TAKE ORAL THERAPY2

  • Avoid treatment disruptions when your patients are unable to take oral therapy by temporarily transitioning them from their current oral dose to IV treatment and returning to UPTRAVI® Tablets when possible2,3
dosing illustration

Remain confident that your patients can receive UPTRAVI® treatment at home, in the hospital, and after discharge

  • Expected to maintain similar UPTRAVI® efficacy and safety, with the exception of infusion-site reactions, when temporarily using UPTRAVI® IV in the hospital2,3
  • Bypass re-titration when transitioning between UPTRAVI® IV and UPTRAVI® Tablets2
dosing table

Administer UPTRAVI® IV twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI® Tablets.

Please see complete UPTRAVI® IV dosing and administration instructions as listed in the full Prescribing Information.

UPTRAVI® IV INSTRUCTIONS FOR USE VIDEO

Watch the video below to learn more about storage, reconstitution, dilution, and administration of UPTRAVI® IV.

Select a Chapter

NOW PLAYING
About UPTRAVI® IV
Storage and Handling
Reconstitution
Dilution
Administration
Important Safety Information

Downloadable Resources

UPTRAVI® IV Instructions for Use Guide

Use this guide to learn about storage, reconstitution, dilution, and administration of UPTRAVI® IV.

UPTRAVI® IV Frequently Asked Questions

Get the answers to your questions about UPTRAVI® IV.

TEMPORARILY SWITCHING TO UPTRAVI® IV FROM UPTRAVI® TABLETS WAS WELL TOLERATED WITH COMPARABLE EXPOSURE TO THE ACTIVE METABOLITE

Study design3

  • Phase 3, prospective, multicenter, open-label, single-sequence crossover study
  • Twenty patients with PAH in FC I-III receiving a stable dose of UPTRAVI® Tablets for ≥28 days prior to enrollment were included
  • Patients were monitored to assess the safety, tolerability, and pharmacokinetics (including exposure to the active metabolite ACT-333679) of switching from a stable dose of UPTRAVI® Tablets to a corresponding dose of UPTRAVI® IV and back to UPTRAVI® Tablets
  • The dosing regimen for UPTRAVI® IV was selected to help patients achieve similar exposure to the active metabolite when compared with UPTRAVI® Tablets
uptravi switch

Baseline patient characteristics (N=20)3

  • Mean age: 57 years
  • Female: 80%
  • Etiology: idiopathic or heritable PAH (70%), PAH-CTD (20%), PAH-CHD (5%), PoPH (5%)
2/3 pie chart
90% pie chart
stable pie chart

Results2,3

Comparable exposure to the active metabolite following UPTRAVI® Tablets and UPTRAVI® IV administration

results line chart
Time to the maximum concentration of the active metabolite was comparable

Safety2,3

  • The transition from UPTRAVI® Tablets to UPTRAVI® IV and back was well tolerated: Patient tolerability was similar between UPTRAVI® IV and Tablets
  • 10% of patients reported infusion-site reactions during UPTRAVI® IV administration, including infusion-site erythema/redness, pain, and swelling